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improve long-term outcome. However, virus eradica-
tion is unlikely to be an achievable goal. Even in
patients who have recovered from HBV infection with
hepatitis B surface antigen (HBsAg) seroconversion,
low-level HBV DNA can be detected in the blood and
liver using sensitive methods such as polymerase chain
reaction (PCR).3,4
Thus, the therapeutic endpoints for hepatitis B treat-
ment are: sustained suppression of HBV replication,
as indicated by HBsAg and hepatitis B e antigen
(HBeAg) loss, decrease of serum HBV DNA of an
undetectable level by a non-PCR method, and remis-
sion of disease, as shown by normalization of alanine
aminotransferases (ALT) and improvement in liver
histology. It must be emphasized that HBsAg loss is
seldom accomplished, and even when it occurs is fre-
quently delayed. In addition, it is unclear what level
HBV DNA should be suppressed to in order that du-
rable response can be achieved and progression of liver
disease can be halted if treatment is stopped. Improve-
ment in liver histology, defined as a decrease in the
histological activity index (HAI) by two or more points
has been used as the primary endpoint in several major
clinical trials of nucleoside/nucleotide analogs. How-
ever, interpretation of liver histology suffers from the
possibility of sampling error, intra- and inter-observer
variability, and the lack of linearity of grading and
staging systems. Moreover, the clinical significance
of a two-point decrease in HAI has not been validated,
and its relevance may be dependent on the initial
HAI.5
Phases of chronic hepatitis B
The course of CHB infection can be conceptualized as
consisting of four phases (Table 1).6 The first phase is
the immune tolerance phase, characterized by lack of
clinical symptoms, high levels of HBV DNA, normal
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Introduction
Chronic hepatitis B (CHB) remains an important global
health problem. There are approximately 350 million
persons chronically infected with hepatitis B virus
(HBV) worldwide.1 During the course of chronic HBV
infection, an estimated 15% to 40% of CHB patients
would develop complications such as exacerbations of
hepatitis, cirrhosis, liver failure, and hepatocellular car-
cinoma (HCC).2
Ideally, the aims of treatment would be to eradicate
the virus, to induce remission of liver disease, and to
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ALT, and minimal histological activity. This phase is
usually seen in children and young adults with
perinatally acquired HBV infection. Treatment is not
recommended, as response rates of current therapy are
poor.7
The second phase is the immune clearance phase,
characterized by HBeAg to anti-HBe seroconversion.
During this phase, immune clearance of HBV occurs
and the destruction of infected hepatocytes may be
manifested as an increase in ALT level. Successful
HBeAg seroconversion is usually accompanied by a
decrease in HBV DNA to low or undetectable values,
and the normalization of ALT levels. However, some
patients fail to achieve spontaneous HBeAg serocon-
version and continue to have prolonged episodes of
elevated ALT levels and active disease in liver histol-
ogy, with repeated hepatitis flares, leading to an in-
creased risk of cirrhosis.8,9 During this phase, patients
should be monitored closely, and if spontaneous
HBeAg seroconversion does not occur after 3 to 6
months of observation, treatment should be initiated.10
The third phase is the inactive carrier state, character-
ized by the presence of anti-HBe, normal ALT, and low
HBV DNA levels that are only detectable by PCR as-
says. Treatment is not indicated, as viral replication is
already suppressed by the host immune response.
Some patients go on to the fourth phase, during which
there is reactivation of HBV replication, characterized
by an increase in serum HBV DNA and ALT levels.
HBeAg remains negative and, hence, this phase is also
known as HBeAg-negative CHB.11 Spontaneous remis-
sion is uncommon and, hence, treatment is generally
indicated.
Management of patients with chronic hepatitis B
Patients with CHB should be counseled regarding
lifestyle modifications and prevention of transmission
(Table 2). Heavy use of alcohol (40 g/day) has been
associated with elevation of aminotransferases and
increased risks of developing cirrhosis and should be
discouraged.12,13 Potential spread of infection through
unprotected sexual intercourse, childbirth, sharing of
intravenous needles, and environmental contamination
from a blood spill should be discussed. Household
members, including spouses, offspring, siblings, and
parents are at increased risk of HBV infection and
should be screened. Vaccination is recommended if
they are seronegative.14
Patients should also be educated on the natural his-
tory and potential long-term complications of chronic
HBV infection. Life-long surveillance of HCC with
both alpha-fetoprotein and ultrasonography should be
considered in high-risk carriers, such as men above the
age of 45 years, persons with cirrhosis, and individuals
with a family history of HCC.
Drug treatment of chronic hepatitis B
Two therapeutic agents, interferon-alpha (IFNα) and
lamivudine, are currently approved in many countries
for the treatment of CHB.
Interferon-alpha
IFN-α, a potent cytokine with antiviral and immunomo-
dulating actions, is produced in response to viral
infection.15,16
Table 1. Four phases of the course of chronic hepatitis B infection
Phase ALT Serum HBV DNA HBeAg
Immune tolerance Normal High Positive
Immune clearance Elevated High to low Positive to negative
Inactive carrier Normal Low Negative
Reactivation Elevated High Negative
HBeAg, Hepatitis B e antigen
Table 2. General management of patients with chronic hepatitis B
1. Avoidance of:
• Heavy alcohol consumption
• Unprotected sexual intercourse with partners who are not vaccinated
• Sharing of needles or other items that potentially contain blood such as shavers or toothbrushes
• Donation of blood or organs
2. Screening of family members and sexual partners for HBV infection and vaccination of those who are seronegative
3. Patient education and long-term follow-up with regular testing of liver biochemistry and surveillance of hepatocellular
carcinoma in high risk groups
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Efficacy in HBeAg-positive chronic hepatitis B.
Metaanalysis of randomized controlled trials involving
patients with HBeAg-positive CHB showed a signifi-
cantly higher response rate with IFN-α as compared
with placebo. Losses of HBeAg and HBsAg were 21%
and 6% more, respectively, in the IFN-α-treated
patients.17 Post-hoc analysis showed that the major pre-
treatment predictors of response were high ALT level,
low HBV DNA levels, female sex, and greater degrees
of activity on liver biopsy.1 Long-term follow-up studies
showed that response was durable in 76% to 94% of
responders and was associated with more favorable
clinical outcomes, in terms of liver-related complica-
tions and survival.18–20
Attempts to induce a high pretreatment ALT level
with steroid priming prior to IFN-α failed to show any
definite improvement in response.21 Besides, steroid
withdrawal in CHB patients may lead to acute exacer-
bation of hepatitis, which can be fatal in patients with
marginal liver reserve. Hence, steroid priming is cur-
rently not recommended in clinical practice.
Extending the treatment duration of IFN-α from
the standard 16-week duration has been attempted to
improve the response rates of IFN-α. A European
study comparing 16-week versus 32-week showed that
longer duration of IFN-α improved response in some
patients.22
Efforts have also been made to use a long-acting
preparation of IFN-α (pegylated interferon) in the
treatment of CHB. Attachment of a polyethylene glycol
polymer to IFN-α decreases its clearance, prolongs
serum therapeutic level, and can potentially enhance its
efficacy. Clinical studies are currently underway and
initial results are promising.23
Efficacy in HBeAg-negative chronic hepatitis B. Four
randomized controlled trials involving 86 IFN-α-treated
patients and 84 controls showed that the end-of-
treatment response ranged from 38% to 90% in the
treated patients compared with only 0% to 37% in con-
trols.24–27 However, the relapse rate was high. Long-term
response was observed in only 20% to 25% of patients.
These responders appear to have a 10% chance of
subsequent HBsAg loss, as well as an improvement in
survival.28
Adverse effects. Adverse effects of IFN-α include consti-
tutional symptoms, such as myalgia, flu-like symptoms,
and fever; neutropenia; thrombocytopenia; mood
changes, such as irritability, anxiety, and depression;
and exacerbation or unmasking of autoimmune dis-
eases. In addition, flares occur frequently in patients
treated with IFN-α, so it is contraindicated in patients
with decompensated liver cirrhosis.29
Lamivudine
Lamivudine (3TC), a nucleoside analogue, is the ()
enantiomer of 2,3-dideoxy 3-thiacytidine. It is phos-
phorylated to the triphosphate (3TC-TP) which com-
petes with dCTP for incorporation into growing DNA
chains, causing chain termination. This may occur dur-
ing reverse transcription of the first strand of HBV
DNA, and during synthesis of the second strand of
HBV DNA. Lamivudine has also been shown to reverse
the T-cell hyporesponsiveness to hepatitis B viral anti-
gens observed in patients with CHB.30
Efficacy in HBeAg-positive chronic hepatitis B.
Lamivudine is taken orally at a dose of 100 mg daily.
A 12-month course of therapy resulted in HBeAg
seroconversion in 16% to 18%, as compared with 4% to
6% in the placebo group.31,32 The HBeAg serocon-
version rate increased to 27% and 40% after 2 and 3
years of therapy, respectively.33,34 Post-hoc analysis
showed that pretreatment ALT was the strongest deter-
minant for response. The rate of HBeAg serocon-
version was 7% when pretreatment ALT was less than
twice normal, 20% for ALT two to five times normal,
and 42% for ALT more than five times normal.35
Preliminary reports suggest that 73% to 86% of
patients remained HBeAg-negative after HBeAg
seroconversion in clinical trials, but some responders
who had early relapse were not included in these follow-
up studies, so these results may be overly optimistic. A
Korean group reported a relapse rate of 49% 2 years
post-treatment.36 A possible reason for this high relapse
rate could be the short duration of lamivudine treat-
ment (mean, 9.3  2.9 months). The duration of
lamivudine treatment after HBeAg seroconversion may
be an important factor determining the durability of
response.
Efficacy in HBeAg-negative chronic hepatitis B.
Lamivudine has been shown to benefit patients with
HBeAg-negative CHB, with virological response in
60%–70% after 12 months of treatment.37–39 However,
relapse was close to 90% upon discontinuation of a
12-month course of lamivudine. On the other hand,
continuation of lamivudine was associated with the
emergence of resistance with breakthrough infection.40
The lack of sustained response after a finite course of
treatment and the development of resistance with
continuous treatment suggest that lamivudine mono-
therapy may not be the optimal treatment for HBeAg-
negative CHB.
Adverse events. Unlike IFN-α, lamivudine is well toler-
ated, with no difference in adverse effects compared
with placebo. However, there are problems associated
with the use of lamivudine. Firstly, the durability of
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response appears to be lower than that with IFN-α
therapy, although definitive data are still lacking.
Secondly, prolonged use of lamivudine is associated
with the selection of lamivudine-resistant mutants. Two
principal mutations can confer such resistance: a
methionine-to-valine or -isoleucine substitution in the
YMDD motif of the catalytic domain of HBV poly-
merase at position 204 and a leucine-to-methionine sub-
stitution at position 180 upstream of the YMDD motif.41
The rate of development of such lamivudine-resistant
mutants increases with the duration of lamivudine treat-
ment. In a multi-center Asian trial, the cumulative rate
of genotypic resistance to lamivudine increased from
17% at 1 year to 69% at 5 years.42 High pretreatment
HBV DNA and ALT levels were found to be predic-
tive factors for the selection of lamivudine-resistant
mutants.43
The emergence of YMDD mutants is associated with
increases in HBV DNA and ALT levels. In general, the
levels are lower than those pretreatment, which is likely
due to suppression of the wild-type HBV by continua-
tion of lamivudine.44 Besides, histological improvement
has been documented even in patients harboring
YMDD mutants.45 However, acute exacerbation occurs
in about 40% of patients at a median period of 24
weeks. Although HBeAg seroconversion may occur
after the development of lamivudine resistance, hepatic
decompensation and, rarely, fatality have been reported
in patients with lamivudine resistance.46 Moreover, a
recent report suggested that the initial histological
improvement might be negated.34
Combination therapy
Combination therapy, i.e., concurrent or sequential
treatment with more than one drug, offers many theo-
retical advantages over monotherapy with either IFN-α
or lamivudine. In particular, using more than one drug
that acts on different parts of the life cycle of the virus
provides more effective inhibition of HBV replication
and may diminish or delay the emergence of drug
resistance.
Three multicenter trials using combination therapy of
lamivudine and IFN-α have been reported.47–49 In the
first two trials, involving 226 and 238 subjects, patients
were given 8 weeks of lamivudine 100mg daily, fol-
lowed by 16 weeks of lamivudine 100mg daily and IFN-
α 10 MU thrice weekly. The results of combination
treatment were not significantly better than those with
monotherapy with either agent alone. Criticisms of
these trials include the timing of IFN-α administration 8
weeks after the commencement of lamivudine and the
short duration of lamivudine (24 weeks), as well as the
timing of repeat biopsy (during versus 28 weeks post-
treatment). In the third trial, involving 151 subjects,
patients were given 24 weeks of IFN-α 9MU thrice
weekly, together with lamivudine 100mg daily, or 52
weeks of lamivudine, 100mg daily. The rate of sustained
response was significantly better in the combination
group than in the lamivudine monotherapy group (33%
vs 15%; P  0.014). Further studies are needed to re-
solve these discrepant results. These studies will deter-
mine the efficacy of combination therapy of lamivudine
and IFN-α using an optimal regimen, including the use
of pegylated IFN.
Other combination studies using two nucleoside
analogues, lamivudine-famciclovir and lamivudine-
adefovir dipivoxil, showed promising results in viral
kinetic studies.50,51
Other immunomodulators
Patients with chronic HBV infection have weak and
restricted T-cell response to HBV antigens. Hence,
therapy that stimulates immune response alone or in
combination with antiviral agents may be effective in
the treatment of CHB.
Thymosin-α, a bovine thymus extract, has been
shown to improve T-cell function in in-vitro studies.52 A
recent metaanalysis involving five clinical trials and 353
patients showed a statistically significant delayed ben-
efit.53 However, there was marked heterogeneity among
the five trials, and two of the trials analyzed were pub-
lished only in abstract forms. Thus, more studies are
needed before thymosin-α can be recommended for the
treatment of CHB.
Other potential immunotherapies include therapeu-
tic vaccines and interleukin-12.54,55
Other nucleoside analogues
Success in lamivudine spurred the search for other
nucleos(t)ide analogues.
Adefovir dipivoxil is the oral prodrug of an acyclic
nucleotide monophosphate analogue, a selective inhibi-
tor of viral polymerases and reverse transcriptases with
broadspectrum antiviral activity against retroviruses,
hepadnaviruses, and herpesviruses.56,57 Importantly, in-
vitro studies showed that adefovir dipivoxil was effec-
tive against both wide-type and lamivudine-resistant
HBV.58
In clinical trials, 12 months of adefovir dipivoxil 10mg
daily was associated with significant response in patients
with HBeAg-positive CHB (12% HBeAg serocon-
version vs 6% in the placebo group), as well as in
HBeAg-negative CHB (51% virological response vs
0% in the placebo group).59 In another study, involving
265 patients with lamivudine-resistant HBV, adefovir
dipivoxil 10mg daily was associated with a median drop
of HBV DNA by 3.5 log at week 24 and 4.0 log at week
48, as well as clinical improvement in terms of liver
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function.60 More importantly, unlike lamivudine, there
has been no report of adefovir dipivoxil-resistant forms
of HBV.61 In trials of adefovir dipivoxil in HIV patients,
at a daily dose of 120 mg, renal toxicity (defined as a rise
of serum creatinine 0.5 mg/dl from baseline) started to
appear after 24 weeks and approached 50% by week
80.62 The 10-mg daily dose in trials of CHB has not been
shown to cause any nephrotoxicity. However, it would
be prudent to collect more safety data from long-term
follow-up studies.
Although the response of adefovir dipivoxil was mod-
est as monotherapy, its potential is great as combination
therapy with lamivudine or IFN-α for treatment-naïve
patients with CHB and as salvage therapy for patients
with lamivudine-resistant HBV.
Many other oral nucleoside analogues are also cur-
rently in their phase II or phase III clinical trials for the
treatment of CHB, e.g., emtricitabine, entecavir, -L-2-
deoxythymidine, val-d-cytosine. Some of these have
also shown antiviral activity against YMDD mutants in
vitro.63,64
Use of antiviral agents according to clinical setting
As mentioned earlier, the current antiviral agents, IFN-
α and lamivudine, are not indicated in the immune tol-
erant and the inactive carrier phase.
HBeAg-positive chronic hepatis B. Because clinical
studies of both IFN-α and lamivudine have revealed
that pretreatment ALT level is an important predictor
of response, it would be logical to offer treatment to
patients in the immune clearance phase who do not
achieve spontaneous HBeAg seroconversion after they
have been observed for 3–6 months. Currently, treat-
ment is only recommended to patients with active liver
disease (ALT  two times upper limit of normal). At-
tending physicians should individualize treatment, after
detailed discussion of the pros and cons of both agents
with the patient, before starting treatment.
IFN-α is usually given subcutaneously for 16 weeks,
in doses of either 5MU daily or 10 MU three times per
week. As mentioned earlier, longer duration of treat-
ment was associated with better response in some
patients. Future studies should evaluate the efficacy of
a longer course of pegylated interferon in the treatment
of CHB.
Lamivudine is given orally at a dose of 100mg daily.
A higher dose, 150 mg twice a day, in association with
other antiretroviral therapy, is needed for patients with
HBV and HIV co-infection. Dose reduction is recom-
mended for patients with impaired renal function. The
optimal duration of lamivudine treatment has not been
established. Cessation of lamivudine shortly after
HBeAg seroconversion is associated with a high relapse
rate. A recent retrospective analysis from Korea
showed that HBV DNA levels of more than 4700 cop-
ies/ml at the time of HBeAg seroconversion were asso-
ciated with a higher rate of relapse.65 However, further
studies are needed to confirm this observation. In
patients who are still HBeAg-positive at month 12,
continuation of lamivudine for another 12 months in-
creased HBeAg seroconversion from 17% to 27%.34
However, the additional 12 months of treatment also
increased the rate of YMDD mutants, from 14% to
40%. Discontinuation of lamivudine before HBeAg
seroconversion leads to the return of HBV DNA to
pretreatment levels and has been reported to be associ-
ated with a flare of aminotransferases in about 17% of
patients. Mortality from hepatic decompensation has
been occasionally reported.66 In deciding whether to
continue lamivudine in patients who fail to develop
HBeAg seroconversion after 1 year of treatment, at-
tending physicians must balance the benefit of increased
response with longer duration of treatment and the
increased rate of emergence of YMDD mutants.
For patients who have developed YMDD mutants,
discontinuation of lamivudine leads to the re-
emergence of wide-type HBV and the return of HBV
DNA and ALT to pretreatment levels. In a follow-up
study from Taiwan, hepatitis flares occurred in 40% of
patients with YMDD mutants at a median duration of
24 weeks after the emergence of YMDD mutants.
Among patients with YMDD mutants, 8/12 patients
with a flare, compared with 0/19 without a flare, devel-
oped HBeAg seroconversion.67 Concerns about relapse
after treatment withdrawal and reports of HBeAg
seroconversion in patients maintained on lamivudine
after the emergence of YMDD mutants, and in-vitro
studies showing that the YMDD mutants have de-
creased replication fitness have prompted recommenda-
tions to continue lamivudine in patients who have
developed resistance. However, recent reports showed
no difference in hepatitis flares, decompensation, or
HBeAg seroconversion between patients who contin-
ued or discontinued lamivudine after the emergence
of YMDD mutants.68 These data should prompt re-
evaluation of the recommendation on the management
of patients with lamivudine resistance. As new antiviral
agents with efficacy against lamivudine-resistant HBV,
such as adefovir dipivoxil, become available, it is envi-
sioned that most patients with lamivudine resistance, in
particular those with evidence of worsening liver dis-
ease, should be switched to these new therapies.60
Table 3 compares the pros and cons of IFN-α and
lamivudine. However, it should be noted that most trials
involving IFN-α defined “response” as HBeAg loss,
whereas trials involving lamivudine usually defined
“response” as HBeAg seroconversion, i.e., HBeAg loss
with appearance of anti-HBe.
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Direct head-to-head comparison of these two agents
in treatment-naïve patients came from a study compar-
ing lamivudine monotherapy, IFN monotherapy, and
lamivudine/IFN combination therapy.47 In that study, a
16-week course of IFN-α and a 1-year course of
lamivudine resulted in HBeAg seroconversion in 19%
and 18%, respectively, indicating that both agents are
equally effective in the treatment of HBeAg-positive
CHB.
HBeAg-negative chronic hepatitis B. IFN-α and
lamivudine have been evaluated in the treatment of
patients with HBeAg-negative CHB. However, HBeAg
loss or seroconversion cannot be used as a therapeutic
endpoint. Sustained response is generally defined as loss
of HBV DNA by unamplified assay, with normalization
of ALT 12 months after cessation of therapy.
Both IFN-α and lamivudine appear to have similar
rates of response—60% to 70%—at the end of 1 year of
treatment. However, the durability of response after
cessation of treatment was only about 20% with IFN-α
and less than 10% with lamivudine. Hence, longer dura-
tion of treatment may be required. But IFN-α is associ-
ated with significant side effects, and the prolonged use
of lamivudine is associated with an increasing rate of
drug resistance, which may ultimately negate the initial
benefits. Thus, better treatment is needed.
Treatment of patients with decompensated
HBV cirrhosis
The only curative treatment in this situation would be
liver transplantation.
IFN-α is contraindicated in patients with decompen-
sated cirrhosis, as flares of ALT during the course of
IFN-α therapy may precipitate acute worsening of liver
functiion.10 Lamivudine treatment does not cause the
usual adverse effects of IFN-α, such as ALT flares,
neutropenia, or thrombocytopenia. Lamivudine has
been studied in patients with decompensated cirrhosis
in the hope that the suppression of HBV replication will
result in decreased hepatic inflammation and improve-
ment in liver function. In addition, decreasing viral load
pretransplant may reduce the risk of recurrent hepatitis
B post-liver transplant. A pilot, uncontrolled study in 35
patients showed that, in patients receiving more than 6
months of lamivudine, liver function, including serum
albumin level and the Child-Pugh score, improved.69
Another retrospective study, reviewing 309 patients
awaiting liver transplantation, confirmed that lamivu-
dine was beneficial in a subset of patients.70 However,
many issues, especially the timing of treatment, need to
be resolved before recommending lamivudine for pa-
tients with decompensated HBV-related liver cirrhosis.
Cessation of treatment may lead to hepatitis flares,
while prolonged use of lamivudine may lead to the
emergence of YMDD mutants and worsening of liver
disease.66,67 Whether adefovir would be a better first-line
treatment in these patients depends on its long-term
safety profile, especially its nephrotoxicity.
Summary
Significant advances have been made in the treatment
of CHB, but long-term response is still limited. Future
treatment of CHB is likely to require combination
therapy. However, many issues, e.g., which agents to use
and in what form of combination, remain to be deter-
mined. In addition, combination therapy must demon-
strate increased efficacy with no added adverse effects
and minimal additional cost.
In conclusion, physicians treating patients with CHB
must understand the natural history of CHB and the
treatment options. Currently, antiviral treatment is
indicated for HBeAg-positive patients in the immune
clearance phase, and for HBeAg-negative patients with
evidence of active liver disease and continued high lev-
els of HBV replication. Treatment is not recommended
Table 3. Pros and cons of interferon-alpha and lamivudine
Interferon-alpha Lamivudine
Pros Finite duration of treatment: Less expensive (if given for 1
4 months year only)
Not associated with selection Minimum adverse effects
of resistant mutations
More durable response Oral therapy
Cons Considerable side effects Duration of treatment may be
during therapy prolonged
Expensive Emergence of resistant HBV with
unknown long-term clinical
consequences
Subcutaneous administration Less durable response
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for patients in the immune tolerance phase or the
inactive carrier state, due to lack of efficacy of current
treatment.
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